Therapeutic and diagnostic agents and their uses
By developing new binding molecules that can efficiently and specifically bind HCMV US28 protein, the problem that existing antiviral drugs are difficult to target HCMV latent viruses is solved, and efficient treatment of HCMV-infected cells is achieved, reducing side effects.
JP2025507271APending Publication Date: 2025-03-18ティーヘルパー·アーエス
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024544984
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-30
- Publication Date
- 2025-03-18
AI Technical Summary
Technical Problem
Existing antiviral drugs are difficult to effectively target the latent virus of human cytomegalovirus (HCMV), and there are problems with drug resistance and toxic side effects.
Method used
Develop novel binding molecules that can efficiently and specifically bind HCMV US28 protein, using these molecules to prepare therapeutic agents that target HCMV-infected cells, reducing side effects on healthy cells.
Benefits of technology
It has achieved efficient targeted treatment of HCMV-infected cells, reduced the toxic side effects on healthy cells, and can adapt to the mutation of different HCMV strains.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides binding molecules, and nucleic acid molecules encoding the binding molecules, that have one or more (preferably all) of highly specific binding to the US28 protein of human cytomegalovirus (HCMV), very low levels of non-specific binding to healthy (uninfected) cells, and / or strain-independent binding capabilities. The binding molecules are designed to bind to a newly identified epitope region within the extracellular domain 1 (ECD1) of the US28 protein of human cytomegalovirus (HCMV), which is the first of four extracellular domains presented by US28, corresponding to positions 1-37 of the US28 protein sequence defined by SEQ ID NO:5. The binding molecules of the present invention have been demonstrated to have excellent binding properties, including specific binding specificity for invasive and / or metastatic HCMV-infected cancers, including breast cancer. In certain preferred embodiments, the binding molecules are selected from antibodies (including, for example, BiTE antibodies) and chimeric antigen receptors (CARs), or functional variants, fragments, fusion proteins, and / or conjugates thereof. Cells expressing the binding molecules are also provided, such as CAR-expressing cells, including CAR-T cells, CAR-NK cells, and CAR-M cells.
Need to check novelty before this filing date? Find Prior Art